ZITHROMAX (azithromycin dihydrate) by Pfizer is drug. Approved for infection. First approved in 1997.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
ZITHROMAX (azithromycin dihydrate) is an injectable macrolide antibiotic approved in 1997 for the treatment of bacterial infections, including community-acquired pneumonia. It works by inhibiting bacterial protein synthesis to achieve bacteriostatic effects against susceptible organisms.
With LOE approaching and no recent spending data available, the brand team is likely focused on defensive strategies and lifecycle management rather than growth initiatives.
drug. [see ]
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)
Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)
Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa
A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
Worked on ZITHROMAX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZITHROMAX offers limited career growth due to its LOE-approaching status and minimal linked job openings. Positions are primarily defensive/maintenance-focused within commercial and sales functions rather than innovative or expansion-oriented roles.